A Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma
NCT ID: NCT06126237
Last Updated: 2023-11-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
PHASE1/PHASE2
120 participants
INTERVENTIONAL
2024-02-28
2026-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of QLS4131 in Patients With Recurrent or Refractory Multiple Myeloma
NCT06500507
Study of CM336 in Relapsed or Refractory Multiple Myeloma Patients
NCT07181239
Safety and Efficacy of Single-agent CC-5013 in Subjects With Relapsed and Refractory Multiple Myeloma
NCT00065351
A Study of QLS32015 in Patients With Recurrent or Refractory Multiple Myeloma
NCT05920876
CDC-501 Therapy in Relapsed or Refractory Multiple Myeloma
NCT00044018
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SEQUENTIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CM313
CM313 injection, subcutaneous
CM313 injection
CM313, subcutaneous injection
CM313 + concomitant medication
CM313 injection, subcutaneous
CM313 injection
CM313, subcutaneous injection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CM313 injection
CM313, subcutaneous injection
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjects diagnosed with multiple myeloma.
* Subjects with measurable lesions.
* Women of childbearing potential with negative pregnancy testing.
* Subjects voluntarily signed the Informed Consent Form and were able to comply with the provisions of this protocol.
Exclusion Criteria
* Vaccinated with live, attenuated vaccine within 4 weeks prior to the first dose.
* Positive for human immunodeficiency virus (HIV) antibodies.
* Syphilis antibody positive.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Keymed Biosciences Co.Ltd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CM313-040101
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.